Vanda Pharmaceuticals' Stock Surges on FDA Approval of Motion Sickness Therapy

Vanda Pharmaceuticals' shares experienced a surge in after-hours trading following the FDA's approval of NEREUS, a therapy developed in partnership with Eli Lilly, for preventing motion-induced vomiting in adults. This approval marks a significant win for Vanda and contributed to the positive stock movement.